Oct 17th 2013 - Edison Investment Research today published a report on Oxford BioMedica (OXB.L, LSE:OXB, LON:OXB) entitled "Clinical Trials Set To Resume Recruitment". In summary, the report says:
Regulatory agencies have given the go-ahead to resume patient recruitment into the ocular clinical trials (including RetinoStat). A rapid resumption was critical since Sanofi's decision on whether to opt-in for RetinoStat will define the company's outlook. The cash runway currently extends to Q214. Our valuation is unchanged at £60.1m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »